Loading…
Reported covered position: None
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
National Defense Authorization Act for Fiscal Year 2024
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
P.L. 118-31 (H.R. 2670): National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
General Discussions related to the Food and Drug Administration's regulation of diagnostics and lab developed test General Discussion related to Medicares payment system for clinical diagnostic laboratory services General discussions related to Multi-Cancer Early Detection technology HR 7085: BIOSECURE Act; all provisions General Discussion related to funding for National Institutes of Health General Discussion related to funding for Centers for Disease Control and Prevention General Discussion related to funding for biosurveillance General Discussions related to the implementation of P.L. 117-167 (HR 4346): Chips and Science Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ILLUMINA, INC. via ILLUMINA, INC.
2024 · first_quarter · Q1
General Discussions related to the Food and Drug Administration's regulation of diagnostics and lab developed test General Discussion related to Medicares payment system for clinical diagnostic laboratory services General discussions related to Multi-Cancer Early Detection technology HR 7085: BIOSECURE Act; all provisions General Discussion related to funding for National Institutes of Health General Discussion related to funding for Centers for Disease Control and Prevention General Discussion related to funding for biosurveillance General Discussions related to the implementation of P.L. 117-167 (HR 4346): Chips and Science Act
Source: Senate LDA
General Discussions related to the Food and Drug Administration's regulation of diagnostics and lab developed test General Discussion related to Medicares payment system for clinical diagnostic laboratory services General discussions related to Multi-Cancer Early Detection technology HR 7085: BIOSECURE Act; all provisions General Discussion related to funding for National Institutes of Health General Discussion related to funding for Centers for Disease Control and Prevention General Discussion related to funding for biosurveillance General Discussions related to the implementation of P.L. 117-167 (HR 4346): Chips and Science Act
National Defense Authorization Act for Fiscal Year 2024
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
National Defense Authorization Act for Fiscal Year 2024
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
National Defense Authorization Act for Fiscal Year 2024
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
H.R. 4420: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Centers for Disease Control and Protection, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness H.R. 4421: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Administration for Strategic Preparedness and Response, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
H.R. 4420: Preparedness and Response Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics and lab developed test General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
H.R. 4420: Preparedness and Response Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Preparing for All Hazards and Pathogens Reauthorization Act
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4420: Preparedness and Response Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Preparing for All Hazards and Pathogens Reauthorization Act
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4420: Preparedness and Response Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics and lab developed test General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Preparing for All Hazards and Pathogens Reauthorization Act
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4420: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Centers for Disease Control and Protection, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness H.R. 4421: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Administration for Strategic Preparedness and Response, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
H.R. 4420: Preparedness and Response Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics and lab developed test General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
H.R. 4420: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Centers for Disease Control and Protection, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness H.R. 4421: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Administration for Strategic Preparedness and Response, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
H.R. 4420: Preparedness and Response Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Public Law No: 117-167 (H.R. 4346- 177th Congress): Supreme Court Security Funding Act of 2022 (f.k.a: The CHIPS and Science Act of 2022); All provisions General Discussions related to export control and trade policy
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions Public Law No: 117-167 (H.R. 4346): Supreme Court Security Funding Act of 2022 (f.k.a: The CHIPS and Science Act of 2022); all provisions Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding General discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology General discussions related to genomic surveillance and pandemic preparedness General discussions related to the Cancer Moonshot Initiative General discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions H.R. 4346: The CHIPS and Science Act of 2022; all provisions
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions Public Law No: 117-167 (H.R. 4346): Supreme Court Security Funding Act of 2022 (f.k.a: The CHIPS and Science Act of 2022); all provisions Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
United States Innovation and Competition Act of 2021
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions H.R. 4346: The CHIPS and Science Act of 2022; all provisions
United States Innovation and Competition Act of 2021
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions Public Law No: 117-167 (H.R. 4346): Supreme Court Security Funding Act of 2022 (f.k.a: The CHIPS and Science Act of 2022); all provisions Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
United States Innovation and Competition Act of 2021
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions
H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions General discussions related to genomics, sequencing and applications for sequencing technologies
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
United States Innovation and Competition Act of 2021
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions
United States Innovation and Competition Act of 2021
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions Public Law No: 117-167 (H.R. 4346): Supreme Court Security Funding Act of 2022 (f.k.a: The CHIPS and Science Act of 2022); all provisions Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
United States Innovation and Competition Act of 2021
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions H.R. 4346: The CHIPS and Science Act of 2022; all provisions
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions
H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions General discussions related to genomics, sequencing and applications for sequencing technologies
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions
H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions General discussions related to genomics, sequencing and applications for sequencing technologies
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: ILLUMINA, INC. · Firm: ILLUMINA, INC.
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
P.L. 118-31 (H.R. 2670): National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
General Discussions related to export control and trade policy General Discussions related to biotechnology and genomics education
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS)
ILLUMINA, INC. via ILLUMINA, INC.
2023 · fourth_quarter · Q4
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
H.R. 4420: Preparedness and Response Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics and lab developed test General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
General Discussions related to export control and trade policy
General Discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Science Foundation (NSF), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ILLUMINA, INC. via ILLUMINA, INC.
2023 · third_quarter · Q3
H.R. 4420: Preparedness and Response Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
General Discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
General Discussions related to export control and trade policy
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Science Foundation (NSF), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ILLUMINA, INC. via ILLUMINA, INC.
2023 · second_quarter · Q2
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
H.R. 4420: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Centers for Disease Control and Protection, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness H.R. 4421: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Administration for Strategic Preparedness and Response, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
General Discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
General Discussions related to export control and trade policy
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Science Foundation (NSF), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ILLUMINA, INC. via ILLUMINA, INC.
2023 · first_quarter · Q1
Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding General Discussions related to the Food and Drug Administration's regulation of diagnostics General Discussion related to Medicares payment system for clinical diagnostic laboratory services General Discussions related to the Cancer Moonshot Initiative General Discussions related to genomic surveillance and pandemic preparedness General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
General Discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
Public Law No: 117-167 (H.R. 4346- 177th Congress): Supreme Court Security Funding Act of 2022 (f.k.a: The CHIPS and Science Act of 2022); All provisions General Discussions related to export control and trade policy
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Science Foundation (NSF), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ILLUMINA, INC. via ILLUMINA, INC.
2022 · fourth_quarter · Q4
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions Public Law No: 117-167 (H.R. 4346): Supreme Court Security Funding Act of 2022 (f.k.a: The CHIPS and Science Act of 2022); all provisions Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding General discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology General discussions related to genomic surveillance and pandemic preparedness General discussions related to the Cancer Moonshot Initiative General discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
ILLUMINA, INC. via ILLUMINA, INC.
2022 · third_quarter · Q3
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
ILLUMINA, INC. via ILLUMINA, INC.
2022 · second_quarter · Q2
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions
General discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology General discussions related to genomic surveillance and pandemic preparedness General discussions related to the Cancer Moonshot Initiative
H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions
ILLUMINA, INC. via ILLUMINA, INC.
2022 · first_quarter · Q1
General discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions General discussions related to genomics, sequencing and applications for sequencing technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLUMINA, INC. via ILLUMINA, INC.
2022 · first_quarter · RA
Legislation and regulations affecting sequencing and array-based solutions for genetic research, clinical and applied markets.
Legislation and regulations affecting sequencing and array-based solutions for genetic research, clinical and applied markets.
Legislation and regulations affecting sequencing and array-based solutions for genetic research, clinical and applied markets.
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Science Foundation (NSF), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE, U.S. Trade Representative (USTR)
General discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology General discussions related to genomic surveillance and pandemic preparedness General discussions related to the Cancer Moonshot Initiative General discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions H.R. 4346: The CHIPS and Science Act of 2022; all provisions
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE, U.S. Trade Representative (USTR)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE, U.S. Trade Representative (USTR)